Compass Pathways PLC
NASDAQ:CMPS

Watchlist Manager
Compass Pathways PLC Logo
Compass Pathways PLC
NASDAQ:CMPS
Watchlist
Price: 7.63 USD 3.53% Market Closed
Market Cap: 732.6m USD

Relative Value

There is not enough data to reliably calculate the relative value of CMPS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CMPS Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.2
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-4.5
Industry
24.2
Forward
-3.1
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-4.7
Industry
23
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-5
Industry
25.5
vs History
0
vs Industry
53
Median 3Y
2.1
Median 5Y
2.4
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
vs History
vs Industry
Median 3Y
-2
Median 5Y
-2.1
Industry
6.1
Forward
-3.2
vs History
vs Industry
Median 3Y
-2
Median 5Y
-2.7
Industry
6.6
Forward
-3.1
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-3
Industry
8.8
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-3
Industry
6.8
vs History
41
vs Industry
48
Median 3Y
4.9
Median 5Y
7.1
Industry
5.7

Multiples Across Competitors

CMPS Competitors Multiples
Compass Pathways PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Compass Pathways PLC
NASDAQ:CMPS
732.5m USD 0 -3.1 -3.1 -3.1
IL
Can Fite Biopharma Ltd
TASE:CANF
168.5T ILS 61 044 186.9 -4 192 122 -4 113 755 -4 104 597.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 067 817 -161 919.3 -196 621.7 -194 378
US
Abbvie Inc
NYSE:ABBV
392.2B USD 6.6 167 16.2 23
US
Amgen Inc
NASDAQ:AMGN
177B USD 4.9 25.3 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
154.1B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.2B USD 9.7 31.1 22.8 23.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.9 -527.7 -574.6 -559.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.4B USD 5.6 17.3 16.5 18.7
AU
CSL Ltd
ASX:CSL
84.8B AUD 3.6 18.9 12.7 15.9
NL
argenx SE
XBRU:ARGX
42.3B EUR 13.7 32.1 55.1 56.6
P/S Multiple
Revenue Growth P/S to Growth
UK
Compass Pathways PLC
NASDAQ:CMPS
Average P/S: 9 511 412.1
Not Available
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
61 044 186.9
140%
436 029.9
FR
Pharnext SCA
OTC:PNEXF
34 067 817
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
10%
1
US
E
Epizyme Inc
F:EPE
2 067.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
13.7
49%
0.3
P/E Multiple
Earnings Growth PEG
UK
Compass Pathways PLC
NASDAQ:CMPS
Average P/E: 44.4
Negative Multiple: -3.1
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 192 122 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 919.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.1
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Compass Pathways PLC
NASDAQ:CMPS
Average EV/EBITDA: 22
Negative Multiple: -3.1
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 113 755 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 621.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
55.1
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Compass Pathways PLC
NASDAQ:CMPS
Average EV/EBIT: 24.1
Negative Multiple: -3.1
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 104 597.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 378 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
56.6
N/A N/A